Page last updated: 2024-09-24

1-(4'-nitrophenyl)-2-aminopropane-1,3-diol

Description

1-(4'-nitrophenyl)-2-aminopropane-1,3-diol: chloramphenicol minus dichloroacetamide side chain; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID92743
CHEMBL ID25280
SCHEMBL ID251728
MeSH IDM0081971

Synonyms (62)

Synonym
BB 0257067
MLS001049025
smr000387020
1,3-propanediol, 2-amino-1-(4-nitrophenyl)-
CBDIVE_003085
CBDIVE_006305
OPREA1_299899
EU-0000552
119-62-0
1, 2-amino-1-(p-nitrophenyl)-
1-(p-nitrophenyl)-2-amino-1,3-propanediol
nsc163951
1, 2-amino-1-(4-nitrophenyl)-
nsc-163951
STK386820
2-amino-1-(4-nitrophenyl)propane-1,3-diol
CHEMBL25280
AKOS000118828
NCGC00246273-01
BBL002381
2-amino-1-(4-nitrophenyl)-1,3-propanediol
einecs 221-001-4
(s(r*,r*))-2-amino-1-(p-nitrophenyl)propane-1,3-diol
nsc 12466
HMS2268H24
1-(4'-nitrophenyl)-2-aminopropane-1,3-diol
unii-8fb0b566g6
8fb0b566g6 ,
ai3-62046
einecs 204-338-1
1,3-propanediol, 2-amino-1-(p-nitrophenyl)-
nsc 163951
(r*,r*)-(1)-2-amino-1-(p-nitrophenyl)propane-1,3-diol
einecs 222-997-3
FT-0600616
FT-0634580
AM20050390
AB00601071-07
SCHEMBL251728
AB00601071-09
AKOS016050620
d-threo-2-amino-1-(4-nitrophenyl)-1,3-propanediol
1,3-propanediol, 2-amino-1-(4-nitrophenyl)-, [r-(r*,r*)]-
OCYJXSUPZMNXEN-UHFFFAOYSA-N
2-amino-1-(4-nitrophenyl)-1,3-propanediol #
phenylaceticacid
cambridge id 5104423
F0322-0027
mfcd00066778
mfcd00007359
2-bromo-6-chlorophenylboronicacid
dextramine
VS-01059
1-(4-nitrophenyl)-2-aminopropane-1,3-diol
(r*,r*)-( inverted exclamation marka)-2-amino-1-(p-nitrophenyl)propane-1,3-diol
SB44222
SY066624
SB79368
DTXSID501020866
EN300-16771
F87036
Z235472440

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency3.98110.044717.8581100.0000AID485294
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency22.38720.177814.390939.8107AID2147
glp-1 receptor, partialHomo sapiens (human)Potency3.54810.01846.806014.1254AID624172
thioredoxin reductaseRattus norvegicus (Norway rat)Potency89.12510.100020.879379.4328AID588453; AID588456
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency11.22020.036619.637650.1187AID1466; AID2242
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency28.18380.00419.962528.1838AID2675
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency11.22023.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency11.22023.548118.039535.4813AID1466
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID198284Evaluated for the inhibition constant determined from the Dixon and slope vs. inhibitor concentration plots; No data1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Analogues of chloramphenicol: circular dichroism spectra, inhibition of ribosomal peptidyltransferase, and possible mechanism of action.
AID198281Evaluated for the concentration required for a 50% inhibition of N-acetyl-L-[14C] phenylalanylpuromycin formation; No data1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Analogues of chloramphenicol: circular dichroism spectra, inhibition of ribosomal peptidyltransferase, and possible mechanism of action.
AID26319pKa value is determined; No data1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Analogues of chloramphenicol: circular dichroism spectra, inhibition of ribosomal peptidyltransferase, and possible mechanism of action.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (26.09)18.7374
1990's3 (13.04)18.2507
2000's1 (4.35)29.6817
2010's6 (26.09)24.3611
2020's7 (30.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research Highlights

Pharmacokinetics (1)

ArticleYear
Pharmacokinetics of chloramphenicol base after oral administration in adult horses.
Journal of the American Veterinary Medical Association, Jul-01, Volume: 251, Issue: 1
2017
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (1)

ArticleYear
Pharmacokinetics of chloramphenicol base after oral administration in adult horses.
Journal of the American Veterinary Medical Association, Jul-01, Volume: 251, Issue: 1
2017
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (1)

ArticleYear
Synthesis, Analytical Characterization and Spectroscopic Investigation of Chloramphenicol Impurity A for the Quality Control of Chloramphenicol and its Formulation as Per International Compendium.
Current organic synthesis, Volume: 17, Issue: 5
2020
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]